Clinical trials: Anthracyclines
Breast Cancer, Metastases
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
- Trial name
- NCT00080262
- Testing
- Ixabepilone
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 125 people
- Sponsor
- R-Pharm
Emesis
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast…
- Trial name
- NCT00869973
- Testing
- Aprepitant, dexamethasone
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- S. Maria Hospital, Terni
Large B-cell Lymphoma
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
- Trial name
- NCT06045247
- Testing
- Prednisone, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
Doxorubicin and other anthracyclines are commonly used to treat breast cancer and other types of cancer. Unfortunately, they can cause heart muscle damage, resulting in scarring, abnormal contraction and relaxation, and heart…
- Trial name
- NCT01708798
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University of British Columbia
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Breast Cancer, Stage I Breast Cancer
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines.
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02096588
- Testing
- Simvastatin, Doxorubicin/cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called…
- Trial name
- NCT04817241
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00275041
- Testing
- cetuximab, irinotecan hydrochloride
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Metastatic Breast Cancer
Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer
HALACAP-1406 is a prospective single-centre non-interventional study assessing the refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®) in the conditions of use specified in its marketing…
- Trial name
- NCT02863146
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Oscar Lambret
Metastatic Breast Cancer
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen
To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer
- Trial name
- NCT00191269
- Testing
- gemcitabine
- Where
- 13 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after…
- Trial name
- NATAN (NCT00512993)
- Testing
- Zoledronic acid
- Where
- 93 sites in Austria, Germany
- Volunteers
- 654 people
- Sponsor
- GBG Forschungs GmbH
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Anthracycline Extravasation
Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines
The purpose of this study is to avoid surgical intervention following extravasation of anthracycline chemotherapy out of a vessel into the surrounding tissues.
- Trial name
- NCT00548561
- Testing
- Dexrazoxane
- Where
- 9 sites in Denmark
- Volunteers
- 23 people
- Sponsor
- Valerio Therapeutics
Acute Promyelocytic Leukemia
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Primary objectives To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL.
- Trial name
- NCT00408278
- Testing
- ATRA, Idarubicina, Mitoxantrone
- Where
- 42 sites in Poland, Spain and 1 more
- Volunteers
- 300 people
- Sponsor
- PETHEMA Foundation
Lymphoma, Heart Failure, Congestive
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function…
- Trial name
- NCT00195897
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Henri Becquerel
Breast Cancer
Irinotecan for Advanced and Metastatic Breast Cancer
This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing…
- Trial name
- NCT03562390
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Acute Promyelocytic Leukemia
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features.
- Trial name
- TUD-APOLLO-064 (NCT02688140)
- Testing
- Arsenic trioxide, Idarubicin, Cytarabine
- Where
- 8 sites in France, Germany and 3 more
- Volunteers
- 133 people
- Sponsor
- Technische Universität Dresden
Breast Neoplasms, Metastases, Neoplasm
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.
- Trial name
- NCT00034918
- Testing
- ZD6474
- Where
- 2 sites in United States, Spain
- Volunteers
- 44 people
- Sponsor
- Genzyme, a Sanofi Company